{
    "1": {
        "question": "What is the main objective of using CRISPR/Cas9 editing in this study?",
        "options": {
            "A": "To enhance the proliferation of NK cells.",
            "B": "To enable NKG2A-mediated immune activation.",
            "C": "To disrupt the KLRC1 gene that encodes for NKG2A.",
            "D": "To increase the expression of CD19 antigen.",
            "E": "To reduce the expression of CD33 antigen.",
            "F": "I don't know."
        }
    },
    "2": {
        "question": "What antigen do the CAR-NK cells specifically target in this study?",
        "options": {
            "A": "CD19",
            "B": "HLA-E",
            "C": "NKG2D",
            "D": "CD33",
            "E": "PD-L1",
            "F": "I don't know."
        }
    },
    "3": {
        "question": "What is the primary function of the NKG2A receptor in NK cells?",
        "options": {
            "A": "To activate the NK cells upon tumor detection.",
            "B": "To inhibit NK cell activation in the presence of HLA-E.",
            "C": "To promote the proliferation of NK cells.",
            "D": "To induce apoptosis in NK cells.",
            "E": "To interact with CD33 antigen.",
            "F": "I don't know."
        }
    },
    "4": {
        "question": "What cell type is reduced by approximately 50% following CRISPR/Cas9 knockout of KLRC1?",
        "options": {
            "A": "CD19-positive cells",
            "B": "NKG2A-positive cells",
            "C": "CD33-positive cells",
            "D": "TIGIT-positive cells",
            "E": "PD-1-positive cells",
            "F": "I don't know."
        }
    },
    "5": {
        "question": "In the study's results, how does the gene expression of CAR33-KLRC1ko-NK cells compare to that of CAR33-NK cells?",
        "options": {
            "A": "Significant upregulation of ZNF683",
            "B": "Increased expression of cytokine receptors",
            "C": "Increased IFN-\u03b3 secretion compared to CAR33-NK cells",
            "D": "Loss of expression of CD33 antigen",
            "E": "Decreased granzyme B levels",
            "F": "I don't know."
        }
    },
    "6": {
        "question": "What type of assays did the study use to evaluate the killing capacity of CAR-NK cells in vitro?",
        "options": {
            "A": "Real-time PCR assays",
            "B": "Short and long-term flow cytometry-based killing assays",
            "C": "Western blot assays",
            "D": "Chromatin immunoprecipitation assays",
            "E": "Enzyme-linked immunosorbent assays (ELISA)",
            "F": "I don't know."
        }
    },
    "7": {
        "question": "What model organism was used for the in vivo evaluation?",
        "options": {
            "A": "Mice",
            "B": "Rats",
            "C": "Rabbits",
            "D": "Primates",
            "E": "Zebrafish",
            "F": "I don't know."
        }
    },
    "8": {
        "question": "What is the role of IFN-\u03b3 in the context of this study?",
        "options": {
            "A": "It inhibits NK cell activity.",
            "B": "It upregulates HLA-E on tumor cells.",
            "C": "It downregulates PD-L1 on tumor cells.",
            "D": "It induces granzyme production in AML blasts.",
            "E": "It serves as a physical barrier between the NK cells and leukemia blasts.",
            "F": "I don't know."
        }
    },
    "9": {
        "question": "What is one potential advantage of CAR-NK cell therapy over CAR-T cell therapy?",
        "options": {
            "A": "Longer lifetime and higher persistence",
            "B": "HLA-independent killing mechanism",
            "C": "More side effects",
            "D": "Ability to target CD8-positive cells",
            "E": "Increased cytokine release syndrome incidence",
            "F": "I don't know."
        }
    },
    "10": {
        "question": "What genetic modification strategy besides the CAR was used in NK cells in this study?",
        "options": {
            "A": "Gene silencing of PD-1",
            "B": "CRISPR/Cas9-mediated KLRC1 knockout",
            "C": "Overexpression of HLA-E",
            "D": "Insertion of cytokine-inducible Src homology 2-containing protein",
            "E": "Knockout of NKG2D",
            "F": "I don't know."
        }
    },
    "11": {
        "question": "How did the CAR33-KLRC1ko-NK cells perform against patient-derived primary AML blast cells compared to other NK cell forms?",
        "options": {
            "A": "They had lower cytotoxicity.",
            "B": "They showed similar cytotoxicity.",
            "C": "They had superior cytotoxic capacity.",
            "D": "They did not engage with the blast cells.",
            "E": "They caused significant side effects.",
            "F": "I don't know."
        }
    },
    "12": {
        "question": "Which gene's knockout is hypothesized to improve anti-AML killing activity?",
        "options": {
            "A": "TNFSF8",
            "B": "CISH",
            "C": "CTLA-4",
            "D": "KLRC1",
            "E": "HAVRC2",
            "F": "I don't know."
        }
    },
    "13": {
        "question": "What specific role does the CAR33-KLRC1ko-NK cells' double genetic modification serve?",
        "options": {
            "A": "Synergetic improvement of cytotoxic capacity and reduction of immune suppression.",
            "B": "Increase in IFN-\u03b3 secretion only.",
            "C": "Promotion of T cell activation.",
            "D": "Enhanced expression of CD19 antigen.",
            "E": "Prevention of NK cell maturation.",
            "F": "I don't know."
        }
    },
    "14": {
        "question": "Which surface marker was analyzed to confirm CAR expression in NK cells?",
        "options": {
            "A": "CD16",
            "B": "CD69",
            "C": "CD33",
            "D": "NKG2D",
            "E": "CD3",
            "F": "I don't know."
        }
    },
    "15": {
        "question": "What is the predominant indel observed after CRISPR/Cas9-mediated KLRC1 knockout?",
        "options": {
            "A": "+5 insertion",
            "B": "-15 deletion",
            "C": "+1 insertion",
            "D": "+10 insertion",
            "E": "-8 deletion",
            "F": "I don't know."
        }
    },
    "16": {
        "question": "What is a potential challenge the AML environment poses to NK cell therapies?",
        "options": {
            "A": "Improved proliferation of NK cells",
            "B": "Inhibition through the NKG2A-HLA-E interaction",
            "C": "Upregulation of CD33",
            "D": "Induction of lymphocyte proliferation",
            "E": "Promotion of NK cell extravasation",
            "F": "I don't know."
        }
    },
    "17": {
        "question": "Which transcriptional feature was observed in CAR33-KLRC1ko-NK cells after AML cell exposure?",
        "options": {
            "A": "Downregulation of cytokines",
            "B": "Overexpression of inhibitory checkpoints",
            "C": "IFN-\u03b3 Type-I signaling signature",
            "D": "Loss of CAR activity",
            "E": "Decreased perforin production",
            "F": "I don't know."
        }
    },
    "18": {
        "question": "Why is the combination of CAR33 expression and KLRC1 knockout considered synergistic in this study?",
        "options": {
            "A": "The combination leads to increased IFN-\u03b3 secretion only.",
            "B": "The combination significantly downregulates CD3.",
            "C": "The combination enhances anti-AML activity not seen with either modification alone.",
            "D": "The combination promotes stronger CAR expression.",
            "E": "The combination leads to NK cell apoptosis.",
            "F": "I don't know."
        }
    },
    "19": {
        "question": "Which significant cytokine was measured after a 4-hour NK cell co-culture with AML cells?",
        "options": {
            "A": "IL-2",
            "B": "Granzyme A",
            "C": "INF-\u03b3",
            "D": "TNF-alpha",
            "E": "IL-12",
            "F": "I don't know."
        }
    },
    "20": {
        "question": "How were the NK cells modified to express CD33-targeting CARs in this study?",
        "options": {
            "A": "Direct DNA microinjection",
            "B": "Lentiviral transduction",
            "C": "CRISPR/Cas9 gene insertion",
            "D": "Protein transfection",
            "E": "Traditional viral integration",
            "F": "I don't know."
        }
    },
    "21": {
        "question": "What is one advantage attributed to non-viral CRISPR/Cas9 system used in NK cells?",
        "options": {
            "A": "Reduces risk of malignant transformation.",
            "B": "Increases NK cell lifespan.",
            "C": "Triggers apoptosis in AML cells more effectively.",
            "D": "Enhances NK cell's ability to detect CD3+ cells.",
            "E": "Leads to 100% NKG2A-positive cells.",
            "F": "I don't know."
        }
    },
    "22": {
        "question": "What percentage of CAR33 expression was seen in NK cells after transduction?",
        "options": {
            "A": "10-30%",
            "B": "30-70%",
            "C": "70-90%",
            "D": "90-100%",
            "E": "Below 10%",
            "F": "I don't know."
        }
    },
    "23": {
        "question": "What does the term 'IMDM medium' refer to in the context of this study?",
        "options": {
            "A": "A media type used to culture AML cells",
            "B": "A specialized NK cell growth serum",
            "C": "A chemical compound used for CRISPR modification",
            "D": "An ingredient in lentiviral transduction formulation",
            "E": "A cytotoxic agent for targeting leukemic cells",
            "F": "I don't know."
        }
    },
    "24": {
        "question": "What phenotype did the CAR33-KLRC1ko-NK cells maintain following exposure to AML cells?",
        "options": {
            "A": "Immature NK cells",
            "B": "T-cell like phenotype",
            "C": "Activated and mature state",
            "D": "Monocyte-like characteristics",
            "E": "Basal phenotype",
            "F": "I don't know."
        }
    },
    "25": {
        "question": "What is the overall survival impact of HLA-E levels according to the study?",
        "options": {
            "A": "Predicted unfavorable survival outcome",
            "B": "No correlation with survival probability",
            "C": "Significantly reduced patient survival",
            "D": "Correlated with improved survival rates",
            "E": "Associated with longer remission periods",
            "F": "I don't know."
        }
    },
    "26": {
        "question": "Which cellular assay shows increased Caspase-3 cleavage in this study?",
        "options": {
            "A": "GFP expression assay",
            "B": "qPCR analysis",
            "C": "Western blot analysis",
            "D": "Cytokine release assay",
            "E": "An IncuCyte imaging assay",
            "F": "I don't know."
        }
    },
    "27": {
        "question": "In the article, what is the key challenge noted about HLA-E's role?",
        "options": {
            "A": "Its ability to increase leukocyte lifespan",
            "B": "Its interaction leading to immune suppression via NKG2A",
            "C": "Its inability to bind NK cell receptors",
            "D": "It promotes the apoptosis of NK cells",
            "E": "Its capacity to trigger autoimmunity",
            "F": "I don't know."
        }
    },
    "28": {
        "question": "What was the purpose of including the NSG-SGM3 mouse model in this study?",
        "options": {
            "A": "To evaluate the CAR33-KLRC1ko-NK activity in a human equivalent environment",
            "B": "To test the regenerative capacity of AML cells",
            "C": "To analyze NK-cell-induced growth factors",
            "D": "To compare CAR-T and CAR-NK efficacy",
            "E": "To measure longer cytokine release",
            "F": "I don't know."
        }
    },
    "29": {
        "question": "What promoter sequence was used in the lentiviral vector?",
        "options": {
            "A": "CMV",
            "B": "EF-1\u03b1",
            "C": "PGK",
            "D": "SV40",
            "E": "RSV",
            "F": "I don't know."
        }
    },
    "30": {
        "question": "What percentage of HLA-E+ AML cells did CAR33-KLRC1ko-NK cells show increased killing activity against?",
        "options": {
            "A": "20%",
            "B": "50%",
            "C": "75%",
            "D": "100%",
            "E": "It is not specified in the study.",
            "F": "I don't know."
        }
    },
    "31": {
        "question": "What is the function of DNAM1 described in the study?",
        "options": {
            "A": "A granzyme involved in cell apoptosis",
            "B": "NK cell receptor involved in cell activation",
            "C": "A cytokine promoting cell recruitment",
            "D": "A protein inhibiting NK cell function",
            "E": "A marker for hematopoietic progenitors",
            "F": "I don't know."
        }
    },
    "32": {
        "question": "Which significant change was noted on introducing CAR in the NK cells?",
        "options": {
            "A": "Loss of CD3 expression",
            "B": "Increased expression of TCR-inducible fingerprints",
            "C": "Promotion of naive T-cell characteristics",
            "D": "Decreased immune checkpoint activity",
            "E": "Increased expression of Zinc Finger Protein",
            "F": "I don't know."
        }
    },
    "33": {
        "question": "What role does Mass cytometry play in this study?",
        "options": {
            "A": "Analyzing infusion kinetics",
            "B": "Determining cytokine affinity",
            "C": "Profiling cell surface markers",
            "D": "Mapping transfection efficiency",
            "E": "Tracking CAR activity over time",
            "F": "I don't know."
        }
    },
    "34": {
        "question": "What was a key conclusion about the dual modification on NK cells as observed in this study?",
        "options": {
            "A": "It promoted NK cell death.",
            "B": "It resulted in a less active state.",
            "C": "It showcased an improved anti-AML capacity.",
            "D": "It enhanced the suppression of NK cell receptors.",
            "E": "It diminished the need for CAR expression.",
            "F": "I don't know."
        }
    },
    "35": {
        "question": "What was significantly observed in CAR33-KLRC1ko-NK cells after the interaction with AML?",
        "options": {
            "A": "Decreased apoptosis rate",
            "B": "Eczema-like skin rashes",
            "C": "Improved cell cycle arrest",
            "D": "Increased cytokine and chemokine expression",
            "E": "Reduction in NK cell receptor expression",
            "F": "I don't know."
        }
    },
    "36": {
        "question": "Which result was noted specifically with CAR33-KLRC1ko-NK in the mouse model?",
        "options": {
            "A": "No impact on tumor proliferation",
            "B": "Significant reduction of leukemia burden",
            "C": "Unrecorded NK activation levels",
            "D": "Increase in HLA-E levels",
            "E": "Induced major weight loss in mice",
            "F": "I don't know."
        }
    },
    "37": {
        "question": "What primary method was used to evaluate NK cell gene expression in this study?",
        "options": {
            "A": "ChIP-Seq",
            "B": "RNA-Seq",
            "C": "Microarray",
            "D": "Proteomics",
            "E": "Fluorometric assays",
            "F": "I don't know."
        }
    },
    "38": {
        "question": "How did the study primarily study protein levels on NK cells?",
        "options": {
            "A": "Western Blotting",
            "B": "Enzyme-linked immunosorbent assay",
            "C": "Mass Spectrometry",
            "D": "Flow Cytometry and CITE-seq",
            "E": "Immunohistochemistry",
            "F": "I don't know."
        }
    },
    "39": {
        "question": "What phenomenon did increased IFN-\u03b3 levels particularly lead to in AML targets?",
        "options": {
            "A": "Decreased HLA-E expression",
            "B": "HLA-E upregulation",
            "C": "More active PKC pathways",
            "D": "Elevation of Granulocyte levels",
            "E": "Enterotoxin resistance",
            "F": "I don't know."
        }
    },
    "40": {
        "question": "Why is the homogenous expression of HLA-E not indicative of survival?",
        "options": {
            "A": "Because NKG2A overcomes this expression.",
            "B": "Due to lack of correlation with leukemia genetic markers.",
            "C": "As it doesn't reflect on immune modulation.",
            "D": "HLA-E only regulates platelet activity.",
            "E": "CD33's activity suppresses its function.",
            "F": "I don't know."
        }
    },
    "41": {
        "question": "What defines the specificity of CRISPR/Cas9 usage observed in this study?",
        "options": {
            "A": "Off-target impact on essential leucine proteases",
            "B": "Prominent occurrence of frame-shifting insertions",
            "C": "Lean selectivity in gene excision and knockout",
            "D": "Highly specific gene targeting with minimal off-targets",
            "E": "Absence of insertion/deletion distribution",
            "F": "I don't know."
        }
    },
    "42": {
        "question": "What is the observed relation between KLRC1 deletion and NKG2A function?",
        "options": {
            "A": "Deleting KLRC1 enhances NKG2A interaction with AML cells.",
            "B": "KLRC1 deletion does not affect NKG2A surface expression.",
            "C": "KLRC1 deletion abrogates NKG2A function partially.",
            "D": "Loss of KLRC1 results in spontaneous CAR degradation.",
            "E": "The deletion drastically reduces NK cell survival.",
            "F": "I don't know."
        }
    },
    "43": {
        "question": "What effect does upregulation of HLA-E on AML cells have in interaction with NK cells?",
        "options": {
            "A": "Boosts NK cell-mediated cytotoxicity.",
            "B": "Induces CAR antigen-specific lysis.",
            "C": "Results in lowered CD69 expression.",
            "D": "Enables NKG2A-mediated immune inhibition.",
            "E": "Modifies leukemic clone diversification.",
            "F": "I don't know."
        }
    },
    "44": {
        "question": "For NK cell-based therapy, what is a cited potential benefit over T-cell based therapies?",
        "options": {
            "A": "Improved tumor antigen recognition.",
            "B": "HLA-identical context dependence.",
            "C": "Low risk of inducing GvHD.",
            "D": "Long duration persistence studies.",
            "E": "Increased cytokine ambient risk.",
            "F": "I don't know."
        }
    },
    "45": {
        "question": "Which key pathway was NOT influenced or altered by CAR33-KLRC1ko-NK cells?",
        "options": {
            "A": "Immune checkpoint pathways",
            "B": "Zinc Finger Protein pathway",
            "C": "Maturation and activation marker pathways",
            "D": "Caspase activation pathway",
            "E": "MAPK signal transduction pathway",
            "F": "I don't know."
        }
    },
    "46": {
        "question": "Which aspect of the NK cells' functionality is highlighted as crucial to bypass immunosuppression?",
        "options": {
            "A": "Increase of interleukin activity",
            "B": "Engagement of DC receptors",
            "C": "Alteration of surface receptor composition",
            "D": "Upregulation of collagen synthesis",
            "E": "Downregulation of CD69",
            "F": "I don't know."
        }
    },
    "47": {
        "question": "What effect did CAR33 and KLRC1 knockout together have on expression of immune suppressive genes?",
        "options": {
            "A": "Upregulation of CTLA-4",
            "B": "Induced PD-L1 expression",
            "C": "Significant reduction of suppressive gene expression",
            "D": "Moderate increase in ZNF683 levels",
            "E": "No observed changes",
            "F": "I don't know."
        }
    },
    "48": {
        "question": "What indication suggests the suppressive effect of the HLA-E/NKG2A axis was overcome in the study?",
        "options": {
            "A": "CAR33-KLRC1ko-NK cells maintained activation despite high HLA-E.",
            "B": "Increased apoptotic body formation",
            "C": "Reduced proliferation rates in NK cells",
            "D": "Downregulated expression of CD25",
            "E": "Enhanced production of nitric oxide synthase",
            "F": "I don't know."
        }
    },
    "49": {
        "question": "What was used to prevent NK cell exhaustion following AML cell co-culture?",
        "options": {
            "A": "Induction of lower HLA dimensions",
            "B": "Class I-I-complex engagement",
            "C": "Non-activated T cell signaling interruption",
            "D": "Lack of upregulation in immune checkpoints like TIM3 and PD-1",
            "E": "Elevation of chemokine entry domains",
            "F": "I don't know."
        }
    },
    "50": {
        "question": "What was the methodology to achieve NKG2A knockout in the study?",
        "options": {
            "A": "Small molecule inhibitors",
            "B": "Monoclonal antibody therapy",
            "C": "CRISPR/Cas9 editing",
            "D": "RNA interference technology",
            "E": "Surface receptor deactivation",
            "F": "I don't know."
        }
    }
}